Serum Institute Gets Nod to Resume Oxford COVID-19 Vaccine Trial
On 11 September, DCGI had ordered SII to suspend any new recruitment in phase two and three clinical trials.
Revoking its earlier order to suspend new recruitment for phase two and three trials, Drugs Controller General of India (DCGI) Dr VG Somani on Tuesday, 15 September, granted the Serum Institute of India the permission to resume clinical trials of the Oxford COVID-19 vaccine candidate in the country.
Adar Poonawalla, CEO, SII said in a tweet, “As I'd mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events is a clear example of why we should not bias the process and should respect the process till the end. Good news.”
On 11 September, the DCGI had ordered the Serum Institute of India to suspend any new recruitment in phase two and three clinical trials of the Oxford COVID-19 vaccine candidate.
On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow the review of safety data by independent committees and international regulators, reported news agency IANS.
Conditions on the Clinical Trial
The DCGI now has put certain conditions on the clinical trial. SII has been advised to take extra care during the screening, provide additional information in informed consent, and closely monitor for adverse events during a follow-up study which has to be “scrupulously” followed by the SII, reported news agency PTI.
The Serum Institute of India is the manufacturing partner of the COVID-19 vaccine among other world-wide vaccine manufacturers, to produce the vaccine currently under trial at the University of Oxford on a mass scale. SII is looking after the trials at 17 trial sites across India.
(With inputs from IANS and PTI)
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)